The test for pancreatic exocrine function using Nbenzoyl-L-tyrosyl-p-aminobenzoic acid (BTP test) 
Introduction
Standard methods of assessing pancreatic exocrine function entail duodenal intubation and analysis of aspirates after direct' or indirect2 stimulation. An oral (tubeless) test of pancreatic function has been developed3 which uses the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid (BTP). Given by mouth, BTP is specifically hydrolysed by chymotrypsin4 to release p-aminobenzoic acid (PABA), which is absorbed and mostly conjugated in the liver before being excreted in urine. Measuring PABA and its metabolites in the urine provides an indirect index of pancreatic exocrine function.
Preliminary studies showed that the BTP test could detect pancreatic disease and that the results correlated well with tests using duodenal intubation.' Nevertheless, misleadingly abnormal results often occur in patients with malabsorption or chronic liver disease because recovery of PABA in urine depends not only on chymotrypsin hydrolysis but also on the absorption and conjugation of PABA.8 Such misleading results can be excluded by performing a second test, replacing oral BTP by PABA, to correct for abnormal PABA absorption and metabolism. 9 This two-day test is cumbersome for clinical use and we have therefore evaluated our suggestion for a single-day test using simultaneous BTP and a tracer dose of '4C-PABA. 9 which was clearly distinct from all nine patients with pancreatic steatorrhoea (excretion index 0-27-0 68) and mixed disease (0-37-0-61). Of the patients with pancreatitis, only four had an abnormal PABA excretion index; but four of the five patients with a normal index also had a normal Lundh test result, so that one patient with chronic pancreatitis, a grossly abnormal Lundh test result, and a cyst in the tail of the pancreas seen at retrograde cholangiopancreatography had a Results Figure 2 shows the recoveries of PABA from BTP for the 51 subjects tested. In normal subjects the range of six-hour urinary PABA recovery was 515-70 00/. All patients with pancreatic steatorrhoea or mixed disease showed lower six-hour urinary PABA recoveries (12- 
Discussion
In over 1200 subjects5-8 12-17 the unmodified BTP test reliably distinguished normal subjects from patients with chronic pancreatitis, though most of the latter had severe exocrine deficiency. Nevertheless, misleadingly abnormal results occur in the presence of other gastrointestinal or hepato-* w 0 biliary disease in 210% and 150% of patients respectively and are more common if steatorrhoea or cirrhosis is present even though exocrine function is normal.8 12 18 Such misleading results are unacceptable for diagnostic purposes and do not occur with tests using duodenal intubation. This test requires only a single six-hour collection of urine and confirms our finding with the two-day test that modification to correct for abnormal PABA metabolism eliminates the misleading results in liver or bowel disease.9 This is important because the detection or exclusion of pancreatic disease in patients who present with symptoms that could be caused by either pancreatic or intestinal disease is a frequent clinical problem. The unmodified BTP test gives an abnormal result only in the presence of severe chronic liver disease, and patients presenting with jaundice are more appropriately investigated by other means. It is encouraging that chronic pancreatitis was indicated in the three patients with coexistent small-bowel and liver disease and that results were as good as with the Lundh test in all but one patient with less severe pancreatitis.
The present test does entail using an isotope, 14C-PABA, but the radiation dose is extremely small. The whole-body dose was estimated at less than 1 mrad (10 tGy) and the organ of reference, which was considered to be the small intestine, receives an estimated dose of 2-5 mrad (25 stGy). We used a high dose of BTP in this study, but other work18 suggests that a 500 mg dose given with 25 g casein improves the separation between groups.
Tetlow et all8 also used this single-day test, and their findings in normal volunteers and patients with chronic pancreatitis were similar to ours. Furthermore, out of 10 patients with non-pancreatic abdominal pain, three had an abnormal BTP test result (grossly so in one patient) but a normal result using the modified test; we thought that patients with nonpancreatic steatorrhoea provided a more rigorous test of the modification. Two other tubeless tests have been advocated, both of which entail longer urine collection times (10-24 hours). The fluorescein dilaurate test'9 also takes two days to perform, and hydrolysis of the diester by pancreatic enzymes may not be specific and is bile dependent. The dual-label Schilling test20 gave good preliminary results but isotope recoveries were low.
An advantage of the single-day modified BTP test, which essentially measures digestive ability, is its relevance to the clinical picture in steatorrhoea. Nevertheless, 900(1 of the pancreas has to be destroyed before steatorrhoea occurs,21 so that theoretically the test should be less sensitive than tests using duodenal intubation; but in practice the tubeless test has also detected most patients with exocrine insufficiency but no steatorrhoea.
Preliminary findings with the test suggest that it may prove useful in detecting pancreatic disease. It is potentially as accurate as conventional tests and avoids duodenal intubation. The practical benefits are a saving in time, facilities, and skill for the clinician and lack of discomfort for patients. Furthermore, the failure rate with tests using duodenal intubation is about 1000 even in the most expert hands. C J Mitchell is in receipt of a grant from the Yorkshire Regional Health Authority. Supplies of isotope from the Radiochemical Centre, Amersham, are gratefully acknowledged. We also thank colleagues who allowed us to study their patients.
